- Wegovy supply is back to normal in 2026 — shortages that affected patients in 2023–2024 have been resolved
- All dose levels (0.25 mg through 2.4 mg) are available through specialty and retail pharmacies
- Zepbound (tirzepatide) remains a strong FDA-approved alternative for patients who prefer a dual-agonist approach
- Compounded semaglutide is not a safe substitute — PEAK does not prescribe it under any circumstances
As of 2026, Wegovy supply has returned to normal. Novo Nordisk has expanded manufacturing capacity, and all dose levels are available through specialty and retail pharmacies. The shortage information below is preserved for historical context, but patients starting or continuing Wegovy should not expect supply disruptions.
Important GLP-1 safety warning: Wegovy carries a boxed warning for thyroid C-cell tumors. Avoid use in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.
If you followed the Wegovy shortage story during 2023 and 2024, you know how disruptive supply gaps were for patients. Demand for semaglutide surged following Wegovy's FDA approval for weight management, and manufacturing could not keep pace. Here is what happened and where things stand now.
The shortage is over. Novo Nordisk invested heavily in expanding production, and supply now meets demand across all dose levels. If you delayed starting treatment because of supply concerns, those barriers are gone.
What the shortage looked like
During the peak shortage periods of 2023 and 2024, certain doses — particularly the 1.7 mg and 2.4 mg maintenance doses — were difficult to obtain. New patients could start at lower titration doses, but stepping up to higher doses sometimes meant delays of weeks. Some patients were forced to pause treatment or switch medications.
As of 2026, this is no longer the case. Novo Nordisk has expanded manufacturing capacity, and all dose levels are now available through specialty pharmacies and major retail chains without extended wait times.
The FDA defines a drug shortage as a period in which total supply does not meet demand. This does not necessarily mean no one can get the medication. It means some patients, at some dose levels, may experience temporary delays in fulfillment. Your clinic’s pharmacy relationships play a major role in how this affects you individually.
During the shortage era, rapid demand growth outpaced manufacturing capacity. More providers prescribed GLP-1 medications, coverage expanded, and the supply chain tightened. Manufacturing expansion later resolved this mismatch.
Why shortages have occurred
Understanding why Wegovy shortages happen helps set realistic expectations about availability. The causes are primarily structural, not quality-related:
- Unprecedented demand. GLP-1 medications have become the most sought-after prescription class in recent memory. The clinical results — averaging approximately 15% total body weight loss in trials — created demand that no manufacturer fully anticipated.
- Complex manufacturing. Semaglutide is a biologic peptide, not a simple small-molecule drug. Manufacturing biologics requires specialized facilities, rigorous quality controls, and long lead times. You cannot simply flip a switch to double production.
- Global distribution. Novo Nordisk serves markets worldwide. Allocation decisions across regions, combined with regulatory requirements in different countries, create a complex distribution puzzle where one market’s increased demand can affect another’s supply.
- Dose-level variability. Each Wegovy dose strength is manufactured separately. Shortages often affect specific doses rather than the entire product line, which is why you might hear that 0.25 mg is available but 2.4 mg is not.
The shortage is a supply-and-demand problem, not a safety problem. When Wegovy is available, it is the same safe, FDA-approved product it has always been.
How PEAK managed patient access during shortages
At PEAK, we did not wait for patients to discover their prescription could not be filled. We monitored supply conditions and took steps to minimize disruptions before they affected treatment.
- Specialty pharmacy relationships. We work with multiple pharmacy partners who prioritize existing patients. This means our patients are often filled ahead of first-time prescriptions at retail pharmacies.
- Advance monitoring. Our care team tracks dose-level availability trends so we can anticipate potential gaps and communicate with you proactively.
- Clinical contingency plans. If your specific dose becomes temporarily unavailable, your clinician can adjust your treatment plan — not by stopping treatment, but by implementing a clinically appropriate bridge strategy.
- Direct patient communication. You will hear from us before a gap affects you, not after. We reach out by phone, text, or through your patient portal with clear guidance on next steps.
No PEAK patient has experienced an unplanned gap in GLP-1 treatment due to supply issues. Our proactive monitoring and pharmacy partnerships are designed to keep your treatment on track, even when broader market conditions are uncertain.
If a dose was temporarily unavailable
During the shortage period, there were rare situations where an exact dose was briefly unavailable. When that happened, this was our clinical approach:
- Do not stop treatment abruptly. Missing doses can lead to appetite rebound and potential weight regain. Your clinician will create a plan to bridge any gap.
- Dose adjustments may be appropriate. In some cases, temporarily using a slightly lower dose is preferable to skipping entirely. This decision is always made in consultation with your PEAK clinician.
- Do not source medication independently. Online pharmacies, telehealth mills, and compounding pharmacies that promise unlimited supply often provide products that are not equivalent to FDA-approved Wegovy. The risks are real and discussed below.
- A clinically guided switch may make sense. If shortages persisted at a dose level, clinicians discussed switching to an alternative FDA-approved medication such as Zepbound.
The most important thing is to communicate with your care team. Do not try to solve supply problems on your own — that is where patients encounter safety risks.
Zepbound as an alternative
Zepbound (tirzepatide) is often mentioned as an alternative to Wegovy, and it is worth understanding how the two medications differ. They are not interchangeable, but Zepbound is a legitimate, FDA-approved option for chronic weight management.
The key difference is in the mechanism. Wegovy (semaglutide) works by activating GLP-1 receptors, which reduce appetite and slow gastric emptying. Zepbound (tirzepatide) is a dual GLP-1/GIP receptor agonist, meaning it activates two incretin pathways simultaneously. In clinical trials, tirzepatide produced slightly greater average weight loss than semaglutide, though individual results vary significantly.
Switching from Wegovy to Zepbound is not as simple as swapping one pill for another. The dosing schedules are different, the titration protocols are different, and insurance coverage varies between the two. Your PEAK clinician will evaluate whether a switch is appropriate for your specific situation, health history, and insurance plan.
If you are interested in exploring Zepbound as an option — whether due to supply concerns or clinical preference — your PEAK clinician can walk you through the differences and help determine if it is the right fit.
Why compounded semaglutide is not safe
During periods of Wegovy shortage, compounding pharmacies have aggressively marketed their own versions of semaglutide. PEAK does not prescribe compounded semaglutide, and we strongly advise patients against seeking it from other sources. Here is why:
- No FDA approval. Compounded semaglutide has not undergone the rigorous clinical trials, manufacturing inspections, and quality assurance processes required for FDA approval.
- Dosing accuracy is not guaranteed. Without standardized manufacturing, the actual dose in each injection can vary — meaning you may be getting more or less medication than intended.
- Sterility concerns. Compounding pharmacies operate under different regulatory standards than manufacturers of FDA-approved drugs. The FDA has documented cases of contamination and sterility failures in compounded products.
- No long-term safety data. The clinical trial data supporting semaglutide’s safety profile applies only to the branded, FDA-approved formulations. Compounded versions may contain different salt forms, fillers, or concentrations.
A medication shortage is never a reason to compromise on safety. There are always better clinical options than unregulated products.
FDA guidance used during shortages
The FDA maintains an active drug shortage database and has been transparent about GLP-1 supply conditions. Their guidance for patients and providers during shortage periods includes several key points:
- Work with your prescriber. The FDA recommends that patients experiencing difficulty filling prescriptions contact their healthcare provider for clinical alternatives rather than seeking medication from unverified sources.
- Avoid unverified online pharmacies. The FDA has issued multiple warnings about fraudulent online sellers offering counterfeit or substandard GLP-1 products, particularly during shortage periods.
- Report adverse events. If you have used a compounded or unverified GLP-1 product and experienced side effects, the FDA encourages reporting through MedWatch.
Our clinical team monitors FDA shortage announcements, safety communications, and supply chain updates in real time. When the situation changes, we adjust our protocols and communicate with affected patients immediately. You do not need to track this yourself — that is our job.
Wegovy supply disruptions were frustrating, but they were manageable with the right clinical partner. At PEAK, patients did not handle these issues alone.
If you delayed treatment during the shortage period, current access should no longer be the barrier it was in 2023–2024. Medication access remains a core part of the care we provide.
